You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 5,856,566

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,856,566

Title:	Sterilized 5-aminolevulinic acid
Abstract:	Colored 5-aminolevulinic acid crystals useful for photodynamic therapy are disclosed. Preferably the colored 5-aminolevulinic acid crystals have the color imparted by irradiation of the crystals, such as gamma radiation. The colored ALA crystals are preferably pharmaceutically pure and sterile and can be contained in a sealed sterile container. Also disclosed is sterile aqueous ALA solution which includes the colored ALA crystals contained in water. Also disclosed is a method for preparing colored ALA crystals which includes exposing non-irradiated ALA crystals to a radiation source at a dose sufficient impart a color which is different than any color present in the non-irradiated crystals. Preferably the irradiation is sufficient to sterilize the ALA crystals. The sterile colored ALA crystals can be used in a kit for internal or external treatment and/or detection of a condition in a mammal, which includes the sterile, colored ALA crystals and sterile diluent, and in the case of internal treatment and/or detection optionally a catheter for administration of the ALA.
Inventor(s):	Golub; Allyn (Miramar, FL)
Assignee:	Dusa Pharmaceuticals, Inc. (Toronto, CA)
Application Number:	08/921,664
Patent Claims:	1. Colored 5-aminolevulinic acid crystals, wherein the color is imparted by irradiation of the crystals. 2. The colored ALA crystals according to claim 1, wherein said crystals are pharmaceutically pure and sterile. 3. The colored ALA crystals according to claim 1, wherein said irradiation is gamma irradiation. 4. The colored ALA crystals according to claim 3, wherein said gamma irradiation is sufficient to sterilize said crystals. 5. The colored ALA crystals according to claim 4, wherein said gamma irradiation provides a dose of at least 5 kilograys. 6. The colored ALA crystals according to claim 4, wherein said gamma irradiation provides a dose of at least 25 kilograys. 7. The colored ALA crystals according to claim 1, wherein said ALA contains less than 2.0 wt % impurities. 8. The colored ALA crystals according to claim 1, wherein said ALA contains less than 1.0 wt % impurities. 9. The colored ALA crystals according to claim 1, wherein said ALA contains less than 0.5 wt % impurities. 10. The colored ALA crystals according to claim 1, wherein said crystals dissolved in an aqueous solution have substantially the same spectroscopic, chromatographic, solution pH and solubility profile as nonirradiated 5-aminolevulinic acid. 11. A sterile ALA solution comprising the colored ALA crystals according to claim 2, contained in a diluent. 12. A sterile package comprising colored ALA crystals according to claim 2 in a sealed sterile container. 13. A sterile package according to claim 12, wherein the container is sterilized by irradiation. 14. A method for preparing colored ALA crystals according to claim 1, comprising exposing non-irradiated ALA crystals to a radiation source at a dose sufficient to impart a color which is different than any color present in the non-irradiated crystals. 15. A method for preparing colored ALA crystals according to claim 14, further comprising: placing non-irradiated ALA crystals into a container; sealing said container; and exposing the non-irradiated ALA crystals and the container to a radiation source at a dose sufficient to impart a color which is different than any color present in the non-irradiated crystals and is sufficient to sterilize said crystals and container. 16. A kit for internal treatment and/or detection of a condition in a mammal, comprising the sterile colored ALA crystals according to claim 2 and sterile diluent. 17. A kit according to claim 16, further comprising a catheter. 18. A kit according to claim 16, wherein the colored ALA crystals are packaged in a sterile container. 19. A method of administering 5-aminolevulinic acid in a stable form for internal and/or external mammal administration which comprises the administration of a solution of ALA derived from the colored ALA according to claim 1. 20. Colored 5-aminolevulinic acid crystals comprising an F-center point defect in the crystal lattice, wherein said F-center point defect imparts said color to the crystals.

Details for Patent 5,856,566

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006	⤷ Try a Trial	2039-09-23
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.